While many focus on tech giants, there are micro-cap plays trading on the Nasdaq with big upside potential. MGRX, CNTG, ATOS, IMUX, and LILM are stocks trading for less than $2 and showing signs of breaking out thanks to solid underlying fundamentals and solid long-term prospects and growth metrics.
Mangoceuticals Strengthens Prospects in Mens Health Market
Mangoceuticals, Inc. (NASDAQ: MGRX) is one of the notable stock movers that’s been breaking out, up 80% from its 2023 lows. The breakout comes as the company continues to make strides in developing, marketing, and selling men’s wellness products and services through its telemedicine platform.
Its uniquely formulated drug, Mango remains the center of attention and a key driver of long-term prospects and underlying value. MGRX has been running an aggressive marketing campaign across the U.S. under the Make America Hard Again banner as it aims to target a broader market to unlock new revenue streams.
While the marketing campaign seeks to unlock new revenue-generating opportunities, it should also help MGRX collect valuable consumer data; which will underpin its future marketing efforts to target consumers through other health and wellness products.
“Our newly launched Make America Hard Again campaign is more than just a new marketing concept–it’s a mantra and a movement as our mission is to help men go hard in every aspect of their lives,” stated MangoRx’s Co-Founder and CEO, Jacob Cohen.
In addition to strengthening its web presence through the new banner, Mangoceuticals is also expanding its marketing drive through sponsorships on podcasts and platforms like Barstool Sports and Gas Digital Network. It’s also seeking additional partnerships, sponsorships, and commercials through well-known nationwide platforms. Mangoceuticals hopes to drive revenues for its core products and merchandise by adding new products to its telemedicine platform and flagship website.
Amid the aggressive marketing campaigns to strengthen revenue streams, Mangoceuticals is also strengthening its product pipeline. It’s fresh from releasing a second Mango product that leverages its existing custom compound alongside Sildenafil, an active ingredient in Viagra.
The new product should be available in the summer and is expected to open up a new revenue stream. The unveiling of the new product affirms MGRX’s intention to establish Mango as a major player in this market.
“Our intent with the launch of this new product is to establish Mango as a legitimate competitor armed with the biotechnology behind Tadalafil and Sildenafil, both of which are the two runaway winners in the ED space over the past two decades,” noted Jacob Cohen, CEO and Co-Founder of MangoRx.
The men’s health market has proven large enough to accommodate multiple competing products. The sector is ripe with attractive opportunities as it grows at a compound annual growth rate of 15%
Centogene Unlocks New Opportunities in Saudi Arabia
Centogene N.V. (Nasdaq: CNTG), an essential life science partner for data-driven answers in rare and neurodegenerative diseases, has been on an impressive run in the market in recent weeks. The stock is already up by more than 100% from its 2023 lows, signaling improving sentiments on Wall Street.
CNTG is fresh from entering a joint venture with Liferay, a biopharmaceutical company, to increase local and regional access and rapid delivery of world-class multi-omic testing for patients in Saudi Arabia. Under the terms of the agreement, CNTG is to receive a $30 million mandatory convertible loan for Liferay, which the Public Investment Fund owns.
The $30 million in funding should strengthen Contagion’s operations, which have evolved to become a market leader in outsourced genetic testing for patients in Saudi Arabia. The strategic collaboration paves the way for the life sciences company to provide leading diagnostics and Multiomics expertise. In return, the two intend to establish widespread access to local state-of-the-art genetic sequencing tailored to regional needs.
Expanding its footprint and operations in Saudi Arabia comes on the heels of CNTG delivering solid full-year 2022 results characterized by a 12% revenue increase to EUR47.5 million. Its growth profit increased to 42% from 32%, with the Pharma and Diagnostics segments poised for a strong 2023 performance and revenues expected to increase by between 10% and 15%.
Atossa Therapeutics Robust Pipeline and Share Buyback Program
Atossa Therapeutics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company focused on developing medicines for unmet medical needs in oncology, has started breaking out. The stock is already up by more than 180% from its May Lows, signaling a buildup in buying pressure.
The rally comes as the biopharmaceutical firm makes impressive strides in the development of its pipeline for unmet medical needs. Its lead program is Endoxifen, an active metabolite of tamoxifen currently on trial for breast cancer treatment. It is also working on AT H201 to treat lung injuries caused by cancer treatment. It is also working on an immunotherapy/chimeric antigen receptor therapy program.
Some of the milestones achieved include the commencement of the Phase 2 clinical trial for the proprietary Selective Estrogen Receptor Modulator Z, endoxifen. Atossa Therapeutic has already achieved a 30 percent enrollment rate within two months. The trial is a collaborative effort involving investigators from major cancer research centers, Quantum Leap Healthcare Collaborative, and the U.S. Food and Drug Administration.
Additionally, the Atossa Therapeutics Board of Directors has a proven $10 million share repurchase program for common stock. The buyback program affirms ATOS commitment to deploying capital to return value to shareholders. It also affirms the strength of the balance sheet to support the back program while also supporting the development programs.
Immunic Makes Progress on Multiple Sclerosis Treatment
Immunic, Inc. (Nasdaq: IMUX) is a Nasdaq penny stock on the move if a 50%+ rally in June is anything to go by. Interest in the biopharmaceutical company focused on developing selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases has been building. Its lead product is IMU 838, which is currently on trial for treating Multiple Sclerosis. It is also developing IMU 935, an inverse retinoic acid receptor-related orphan nuclear receptor agonist.
Phase 2 trials of IMU 838 showed clinically significant therapeutic activity, with Immune reporting positive Phase 2b data on its use for treating ulcerative colitis. IMU 856 is another novel treatment under trial that has already exceeded expectations by showing positive activity in Phase 2b trials to treat ongoing active celiac disease.
Immunic is also advancing biofluidic calcium for the treatment of multiple Sclerosis. Clinically significant activity has been observed in trials with novel therapies showcasing safety and tolerability. Consequently, biofluidics has the potential to be a treatment option for multiple Sclerosis.
Lilium eVTOL Jets on High Demand Amid China Expansion
Lilium N.V. (NASDAQ: LILM) is one penny stock that has recouped all the losses accrued in 2023 after a 300% plus rally from its all-time lows. The developer of the first all-electric vertical takeoff and landing eVTOL jet has seen its sentiments in the market improve on securing $250 million financing that extends its cash runaway towards coming up with the first manned flight as part of the Lilium Jet program.
Lilium is already expanding its footprint into China with the signing of an MOU with the Bao’an District of Shenzhen Municipality. The agreement establishes a safe and sustainable eVTOL service with the Lilium Jet in China. The opening of a hub in China allowed the company to expand its footprint, expected to facilitate the sale of Lilium Hats services and support in the area.
China presents a tremendous opportunity for the eVTOL industry, accounting for more than 25% of the market. Lilium already enjoys strong interest in the Lilium Jet program with multiple customers across Europe, South America, and the Middle East.
The developer of all-electric vertical takeoff and landing jets has also signed an agreement with Shenzhen Eastern General Aviation, Heli Eastern. The operator of a low-altitude general aviation carrier and helicopter service provider is to acquire up to 100 Lilium Jets.
Under the terms of the agreement, Heli Eastern is to help Lilium identify potential sites and partners for vertiports and other ground infrastructure. The new agreement affirms the expansion drive as Lilium Continues to unlock new revenue opportunities.
Lilium is also expanding its footprint in Europe, having partnered with UrbanV, the leader in vertical port design and management, for the development of Advanced Air Mobility infrastructure in Italy and the French Riviera. LILM intends to launch its operations in the two areas with the potential of expanding to other markets.